- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00611572
GABA-glutamate Interactions and Psychosis
July 21, 2022 updated by: Yale University
Contribution of Gabaergic and Glutamatergic Mechanisms to Cognitive Dysfunction
This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
West Haven, Connecticut, United States, 06516
- VHA Connecticut
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion criteria:
- Ages of 21-45 years from all ethnic backgrounds.
- Male or female.
- Written informed consent.
Exclusion criteria:
- DSM-IV diagnosis for a psychotic, depressive or anxiety disorder.
- A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic abnormality, seizure disorder. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, LFTs, TFTs, UA, Utox).
- History of abnormal EEG.
- History of severe allergies or multiple adverse drug reactions.
- Any medication that could interfere with either the safety of the study and/or the outcome measures.
- Any other conditions which in the opinion of the investigator would preclude participation in the study.
- History of major psychiatric disorder in first degree relatives.
- Current substance abuse/dependency determined by urine toxicology.
- Treatment with medications with CNS effects.
- Treatment with benzodiazepines within one week prior to testing.
- Current treatment with medications with psychotropic effects.
- Education < 10th grade.
- IQ < 70, MR.
- Non-English speaking.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Active iomazenil and ketamine
|
Given as IV infusion
saline IV infusion
|
Placebo Comparator: 2
placebo iomazenil and ketamine
|
Given as IV infusion
saline IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
P300 as an ERP measure
Time Frame: prospective
|
prospective
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MMN (Mismatch Negativity)
Time Frame: prospective
|
prospective
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mohini Ranganathan, M.D., Yale School of Medicine, Associate Professor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
October 2, 2018
Study Completion (Actual)
October 2, 2018
Study Registration Dates
First Submitted
January 29, 2008
First Submitted That Met QC Criteria
January 29, 2008
First Posted (Estimate)
February 11, 2008
Study Record Updates
Last Update Posted (Actual)
July 22, 2022
Last Update Submitted That Met QC Criteria
July 21, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0508000517
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Dysfunction
-
Loma Linda UniversityCompleted1. Postoperative Cognitive DysfunctionUnited States
-
Mu Dong LiangNot yet recruitingPostoperative Cognitive Dysfunction(POCD)
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingPOCD - Postoperative Cognitive DysfunctionChina
-
HealthPartners InstituteCompletedPost Operative Cognitive DysfunctionUnited States
-
Burcu Ozalp HorsanaliCompletedPost Operative Cognitive Dysfunction
-
ImmunoChem Therapeutics, LLCNational Cancer Institute (NCI); Northwestern MedicineRecruitingCognitive Dysfunction, Cognitive DisorderUnited States
-
Xijing HospitalFirst Affiliated Hospital Xi'an Jiaotong University; Shanghai 10th People's... and other collaboratorsTerminatedPost Operative Cognitive DysfunctionChina
-
Icahn School of Medicine at Mount SinaiNational Institute on Aging (NIA)CompletedPost Operative Cognitive DysfunctionUnited States
-
Attikon HospitalCompleted
-
Mayo ClinicCompletedCognitive Impairment | Mild Cognitive Impairment | Neurocognitive DysfunctionUnited States
Clinical Trials on iomazenil
-
Yale UniversityCompletedMental Disorders | Psychotic Disorders | SchizophreniaUnited States
-
VA Office of Research and DevelopmentActive, not recruitingActive Ethanol and Active Iomazenil | Active Ethanol and Placebo Iomazenil | Placebo Ethanol and Placebo Iomazenil | Placebo Ethanol and Active Iomazenil | Driving Under the Influence | Alcohol Impairment | Alcohol EffectUnited States